• Finance Tax Investment

Pharma looks to UK for innovation as global economic uncertainty hits fundraising

As global macroeconomic uncertainty hit fundraising across all sectors, investment in UK biotech fell from the all-time highs seen in 2021, new analysis from the UK BioIndustry Association (BIA) and data and insights company Clarivate shows. However, global pharma and investors looked to UK innovation to strengthen their product pipelines, with UK biotechs being acquired at a premium and others achieving pivotal milestones in their development.

Acquisition of Hinshelwood Building to provide additional space at The Oxford Science Park

The Oxford Science Park (TOSP), one of Europe's leading locations for science and technology companies, has further expanded its capacity to accommodate innovative firms with the acquisition of the Hinshelwood Building.

CEO Update | 23 January 2023

This week is one of the busiest in the BIA calendar as we host our much looked-forward-to Gala Dinner, get ready to publish last year's finance figures for the sector and gather our new Board for the first time in 2023. More on all this in next week’s Newscast. I look forward to seeing over 600 of you on Thursday night at the Brewery. Read on for AMR national action plan and how CGI blockbuster, Avatar, is in fact important life science work.

CEO Update | 16 January 2023

It was great to see the UK out in force at the annual JPM conference in San Francisco last week, especially at the reception we hosted with the Government at the Marines' Memorial Club. With over 300 attendees, I know many of you found meeting BioNTech founder and CEO Uğur Şahin a highlight. It was great to learn that BioNTech is opening space in Cambridge, UK and marked their JPM week with the announcement of the acquisition of UK AI start-up InstaDeep in £562 million deal.

Harnessing the economic potential of UK life sciences

This week, the British Business Bank was pleased to announce that our commercial subsidiary British Patient Capital made its first investment from the Life Sciences Investment Programme into the SV Biotech Crossover Opportunities Fund (SV BCOF). Read this blog to learn more!

Japanese funding boost to Eagle Genomics’ scale-up strategy

Japan-based corporate venture capital firm OMRON Ventures has pumped unspecified investment into Cambridge-based Eagle Genomics.

British Patient Capital and Mubadala invest in SV Biotech Crossover Opportunities Fund

British Patient Capital and Mubadala Investment Company (Mubadala), an Abu Dhabi-based sovereign investor, today announced their investment into the SV Biotech Crossover Opportunities Fund (SV BCOF). The co-investment between the two entities is being made through the UK’s Life Sciences Investment Programme (LSIP), which was launched in 2021 to support the growth of UK life sciences businesses.

CEO Update | 9 January 2023

I write this week from San Francisco where the JPM conference is now well underway – with full participation from the UK ecosystem. Folk are already talking about  the announcement of BioNtech’s MoU with the UK Government to develop next generation cancer vaccines in partnership. Also demonstrating the UK’s capability in accelerated innovation is the news from RQ Bio and AstraZeneca that the first of RQ’s monoclonal antibodies to prevent COVID-19 in vulnerable patients, which originates from work of the BIA Antibody Taskforce, has entered clinical trials less than 12 months after discovery, with the start of AZ’s SUPERNOVA Phase I/III trial.

CEO Update | 19 December 2022

Reflections on 2022 and look forward to 2023. Our life science sector is continuing to deliver world-changing products and services at a pace and scale that will transform lives in the years to come. And whether the breakthrough highlighted be next-generation products for type 2 diabetes, novel malaria vaccines, new developments in mRNA vaccinology or cell and gene therapy for the early diagnosis of cancer, I see the UK innovation ecosystem engaged and involved in world-leading programmes.

CEO Update | 12 December 2022

The Chancellor of the Exchequer, Jeremy Hunt MP, unveiled a broad package of measures on financial services last Friday with much that has relevance to the scale up agenda. A lot of different measures were announced that combined, I hope, will unlock new streams of significant investment into UK life science companies. This is a long-term agenda the BIA has been working on behind the scenes for months and years. Read on for an update on Labour’s Policy Day, R&D tax credit campaign and more...